Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT04603248Completed
- Sponsor
- Yonsei University
- Start
- Dec 2020
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of nivolumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Yonsei University. Primary endpoints: Biomarkers to predict objective response (OR) up to 100 months, Biomarkers to predict progression-free survival (PFS) up to 100 months and 1 more. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04603248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603248.